Phenotypic characteristics of exacerbations in severe asthmatics receiving biological agent treatment
Main Article Content
Keywords
Asthma, Disease exacerbation, Mepolizumab, Omalizumab, Phenotype
Abstract
Introduction: Identifying the eosinophilic, neutrophilic, or infectious phenotypes of exacerbations, particularly those occurring during biologic agent therapy, may provide valuable guidance for determining maintenance therapy for patients and preventing recurrent exacerbations. Our study primarily aimed to evaluate the clinical phenotypic features of exacerbations in patients with severe asthma receiving biologic agent therapy.
Methods: The first asthma exacerbation experienced by the patients after the 16th week of biological agent treatment was evaluated in terms of inflammatory phenotype and clinical features. White blood cell counts and C-reactive protein levels, related season, antibiotic use, and hospitalization during the exacerbation were recorded from patients’ medical file records.
Results: Data of 75 patients with severe asthma receiving biological treatment were analyzed. Subjects were aged 48.0 (mean) ± 11.0 (standard deviation), and 52 (69.3%) of them were female. Biological agent used in treatment was omalizumab in 53 (70.7%) subjects and mepolizumab in 22 (29.3%) subjects. The majority of exacerbations in asthmatics treated with either biologic agent were eosinophilic. In patients using omalizumab, the median eosinophil count was significantly higher compared to those using mepolizumab (p=0.032).
Conclusion: Phenotyping of asthma exacerbations that persist in spite of biologic therapy will guide treatment adjustments and decisions to switch biologic agents to improve outcomes.
References
2 Asthma Mortality 2022 [Internet]. The Global Asthma Report; 2022 [cited 2025 Mar 10]. Available from: http://www.globalasthmareport.org/burden/mortality.php
3 Global Initiative for Asthma (GINA). Difficult-to-treat and severe asthma in adolescent and adult patients. Global strategy for asthma management and prevention [Internet]. 2024 [cited 2025 Jan 13]. Available from: https://ginasthma.org/
4 Panettieri RA Jr, Wechsler ME, Wenzel SE. Clinical issues in severe asthma: debates and discussions about personalizing patient management. Chest. 2018;154(6):1459–1460. 10.1016/j.chest.2018.09.002
5 Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat. Med. 2012;18(5):716–25. 10.1038/nm.2678
6 Kuruvilla ME, Lee FE, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin. Rev. Allergy Immunol. 2019;56(2):219–233. 10.1007/s12016-018-8712-1
7 Denton E, Price DB, Tran TN, Canonica GW, Menzies-Gow A, FitzGerald JM, et al. Cluster analysis of inflammatory biomarker expression in the international severe asthma registry. J. Allergy Clin. Immunol. Pract. 2021;9(7):2680–2688.e7. 10.1016/j.jaip.2021.02.059
8 Ray A, Camiolo M, Fitzpatrick A, Gauthier M, Wenzel SE. Are we meeting the promise of endotypes and precision medicine in asthma? Physiol. Rev. 2020;100(3):983–1017. 10.1152/physrev.00023.2019
9 Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur. Respir. J. 2014;43(2): 343–73. 10.1183/09031936.00202013
10 Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur. Respir. J. 2020;55(1):1900588. 10.1183/13993003.00588-2019
11 World Health Organization. Body mass index [Internet]. Global Health Observatory (GHO); [cited 2025 Mar 10]. Available from: https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/body-mass-index
12 McDowell PJ, Diver S, Yang F, Borg C, Busby J, Brown V, et al. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. Lancet Respir. Med. 2021;9(10):1174–1184. 10.1016/S2213-2600(21)00004-7.
13 Coates TD. Approach to the patient with neutrophilia [Internet]. In: Newburger P, Rosmarin AG, editors. UpToDate; 2024 Jun 28 [cited 2025 Mar 10]. Available from: https://www.uptodate.com/contents/approach-to-the-patient-with-neutrophilia
14 Couillard S, Jackson DJ, Pavord ID, Wechsler ME. Choosing the right biologic for the right patient with severe asthma. chest. 2025;167(2):330–342. 10.1016/j.chest.2024.08.045
15 Porsbjerg C, Melén E, Lehtimäki L, Shaw D. Asthma. Lancet. 2023 Mar 11;401(10379):858–873. 10.1016/S0140-6736(22)02125-0
16 Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J. Allergy Clin. Immunol. 2015 Apr 135(4):896–902. 10.1016/j.jaci.2014.08.042
17 Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, et al. Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. J. Allergy Clin. Immunol. 2015;136(6):1488–1495. 10.1016/j.jaci.2015.07.046
18 Doroudchi A, Pathria M, Modena BD. Asthma biologics: comparing trial designs, patient cohorts and study results. Ann. Allergy Asthma. Immunol. 2020;124(1):44–56. 10.1016/j.anai.2019.10.016
19 McGregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma. Am. J. Respir. Crit. Care Med. 2019;199(4):433–445. 10.1164/rccm.201810-1944CI
20 Pelaia C, Pelaia G, Longhini F, Crimi C, Calabrese C, Gallelli L, et al. Monoclonal antibodies targeting alarmins: a new perspective for biological therapies of severe asthma. Biomedicines. 2021 Aug 29;9(9):1108. 10.3390/biomedicines9091108
21 Scioscia G, Nolasco S, Campisi R, Quarato CMI, Caruso C, Pelaia C, et al. Switching biological therapies in severe asthma. Int. J. Mol. Sci. 2023;24(11):9563. 10.3390/ijms24119563
22 Salter B, Lacy P, Mukherjee M. Biologics in asthma: a molecular perspective to precision medicine. Front. Pharmacol. 2022;12:793409. 10.3389/fphar.2021.793409
23 Oishi K, Hamada K, Murata Y, Matsuda K, Ohata S, Yamaji Y, et al. A real-world study of achievement rate and predictive factors of clinical and deep remission to biologics in patients with severe Asthma. J. Clin. Med. 2023;12(8):2900. 10.3390/jcm12082900
24 Basagaña M, Martínez-Rivera C, Padró C, Garcia-Olivé I, Martínez-Colls M, Navarro J, et al. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis. Ann. Med. 2024;56(1):2317356. 10.1080/07853890.2024.2317356
25 Riccardi E, Guida G, Garino S, Bertolini F, Carriero V, Brusamento M, et al. Biologics in T2 severe asthma: unveiling different effectiveness by real-world indirect comparison. J. Clin. Med. 2024;13(16):4750. 10.3390/jcm13164750
